AMERICAN HEAD AND NECK SOCIETY
ADVANCED TRAINING COUNCIL
FELLOWSHIP PROGRAM APPLICATION
NAME AND ADDRESS OF INSTITUTION APPLYING:
Name:
Address:
City, State, Zip:
Head and Neck Tumor Center, Hollings Cancer Center, Medical
University of South Carolina
135 Rutledge Avenue, MSC 550
Charleston, SC, 29425
NAME AND ADDRESS OF FELLOWSHIP PROGRAM DIRECTOR:
Name:
Address:
Terry A. Day, MD, FACS
135 Rutledge Avenue, MSC 550
City, State, Zip: Charleston, SC, 29425
Number of Fellows requested per year: 2
Tenure of Fellowship: ____X____ 1 yr ________ 2 yr
A. GENERAL HOSPITAL INFORMATION
1. Hospital(s): List your principal hospital(s) and all affiliated hospitals:
Principal Hospital(s) Name Total Beds Total #OP Visits Total Cancer Admissions
__MUSC Hospital________ _696___ __950,000____ (Linda Cope)
Affiliated Hospital(s) Name Total Bed Total #OP Visits Total Cancer Admissions
_Ralph H. Johnson VAMC_ _117___ __659,000____ (Peggy Leveen)
2. Approved Residency Programs
General Surgery
Otolaryngology
Plastic Surgery
Dental
Medical Oncology
Own
__X_
__X_
__X_
__X_
__X_
Affiliated
______
______
______
______
______
Pathology
Diagnostic Radiology
Pediatrics
Therapeutic Radiology __X_
Opthalmology
Own
__X_
__X_
__X_
__X_
Affiliated
_______
_______
_______
_______
_______
1

Thoracic Surgery __X_ _______ Neurosurgery __X_ _______
3. Other related existing or proposed fellowships at your institution:
Skull Base Surgery ______________ Plastic Surgery ______X_______
Microsurgery
4.
______________ Surgical Oncology ______________
The type of approval of cancer program by the American College of Surgeons:
Provisional _____________ 3 year ______X______ None _____________
B. FELLOWSHIP BASIC INFORMATION
1. Check clinical services available to fellowship program:
Otolaryngology
Own
____X_____
Affiliated
___________
General Surgery
Radiation Oncology
Medical Oncology
Plastic Surgery
Microvascular Surgery
Dental Prosthodontics
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
___________
___________
___________
___________
___________
___________
Speech Rehabilitation
Physical Therapy
Social Services
Psychiatry
Dietetics
Neurosurgery
Specialized Head & Neck Nursing
Thoracic Surgery
Data Collection - Statistics
Surgical Pathology
Vascular Surgery
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
____X_____
___________
___________
___________
___________
___________
___________
___________
___________
___________
___________
___________
2

1.
3.
Immunology
2. Multidisciplinary Activities:
____X_____ ___________
Describe the referral pattern within your institution(s). Discuss the participation of the radiation oncologist and medical oncologist. Does each discipline see all head and neck patient cancer patients within the institution? Are there multidisciplinary weekly conferences or committees such as tumor boards?
-- All referrals to MUSC for head and neck cancer are initially processed centrally through the department’s Head and Neck Tumor Program Nurse Coordinator. Patients will typically be referred for initial evaluation by one of our five Head and Neck
Surgeons. Depending on the patient’s profile, initial evaluations may also be performed by other specialists within our multidisciplinary Head and Neck Tumor team, such as a
Radiation or Medical Oncologist. Initial appointment selection is based upon treatment related guidelines for the patient’s complaint. All new patients are then presented at our weekly Multidisciplinary Head and Neck Tumor Board meeting. This meeting facilitates review of each new patient’s case by representatives from all the disciplines involved in care of head and neck cancer patients at MUSC, including Head and Neck Surgery,
Medical Oncology, Radiation Oncology, Neuradiology, Pathology, Speech and Language
Therapy and Social Work. Treatment recommendations are formulated with input from all of the services represented, and appropriate consultations and follow-up appointments are planned. Dedicated Head & Neck nurse navigators facilitate arrangement of followup and consultations based on the Head and Neck Tumor Board’s recommendations.
Describe interdisciplinary surgical activities as they currently exist in the head and neck program:
-- The Head & Neck surgery service frequently collaborates with other surgical services at MUSC based on the individual needs of the patient. The Head & Neck Surgery
Fellows will commonly have opportunities to work with surgical staff from other specialties in cases where multidisciplinary surgical expertise is required. Depending on the site and type of the tumor, the Fellows will have the chance to work with surgeons from the following specialities: Neurosurgery, Dermatologic Surgery, Oral and Maxillofacial
Surgery, Opthalmology, Thoracic Surgery, Vascular Surgery, Plastic Surgery and
Orthopedic Surgery. The Head and Neck Surgery program is very inclusive in its approach, and fellows and residents from complementary surgical fields are invited to participate in all surgical activities.
C. FELLOWSHIP PROGRAM RESEARCH INFORMATION
Is laboratory research in head and neck cancer carried out in the institution?
Yes ____X___ No ________
If yes, briefly describe program or projects funding sources. List basic science peer reviewed oncology publications in the past three years.
-- MUSC has multiple on-going, funded laboratories doing research on basic science and translational research related to Head and Neck Cancer. Currently, funded laboratory projects on Head and Neck cancer are headed by the following MUSC researchers:
3


Andrew Jakymiw PhD – Assistant Professor, Department of Craniofacial Biology
( NIH/NIDCR )

Keith L. Kirkwood DDS, Phd – Professor & Chair, Department of Craniofacial
Biology ( NIH/NIDCR/NCRR )

Bonnie Martin-Harris , PhD, CCC-SLP, BRS-S, ASHA Fellow – Professor of
Otolaryngology ( NIDCD )

Besrim Ogretmen, PhD – Professor, Department of Biochemistry and Molecular
Biology (NIH)

Viswanathan Palanisamy PhD – Assistant Professor, Department of Craniofacial
Biology (NCRR/NIDCR)

Sue G. Reed DDS, PhD – Associate Professor, Department of Pediatrics
(NIH/NIDCR)

Steven A. Rosenzweig, PhD – Professor, Department of Cell and Molecular
Pharmacology and Experimental Therapeutics (NIH/NCI/NCRR/DOD)

M. Rita I Young, PhD – Professor, Department of Otolaryngology (NIH/NIDCR/NCI)
-- Basic science, peer-reviewed publication related to Head and Neck Oncology published by MUSC faculty members in the last three years include the following:
Clark, J.I., Eisner, R.M., Hofmeister, C., Norton, J., Thomas, S., Choudhury, A.,
Petruzzelli, G., Lathers, D., Young, M.R.I., Lau, A., Emami, B Phase I adjuvant radiation with docetaxel in high risk head and neck cancer. Am J Clin Oncol, 32:396-400, 2009.
De Costa, A.-M., Justis, D.N., Schuyler, C.A., Young, M.R.I. Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.
Int Immunopharmacol, 13:322-330, 2012.
De Costa, A.-M. A., Young, M.R.I. Immunotherapy for head and neck cancer: advances and deficiencies. Anti-Cancer Drugs, 22: 674-81, 2011, 2011.
De Costa, A.M., Schuyler, C.A., Walker, D.D., Young, M.R.I. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 61:927-939, 2012.
Kulbersh, J.S., Day, T.A., Gillespie, M.B., Young, M.R.I. 1α,25-Dihydroxyvitamin D
3
to skew intratumoral levels of immune inhibitory CD34 + progenitor cells into dendritic cells.
Otolaryngology – Head Neck Surg., 140: 235-240, 2009.
Mailloux, A.W., Young, MRI. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J. Immunol., 182: 2753-1765,
2009.
4

Mailloux, A.W., Clark, A.-M., Young, M.R.I. NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22secreting CD11b + CD11c + cells. Int J Cancer, 127:2598-25611, 2010.
Mailloux, A.W., Young, M.R.I. Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit. Rev. Immunol., 30:435-447, 2011.
Mulligan, J.K., Day, T.A., Gillespie, M.B., Rosenzweig, S.A., Young, M.R.I.
Secretion of
VEGF by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum. Immunol, 70: 375-382, 2009.
Mulligan, J.K., Rosenzweig, S.A., Young, M.R.I. Tumor secretion of VEGF induces endothelial cells to suppress T-cell functions through the production of PGE
2
. J.
Immunother., 33:126-135, 2010.
Mulligan, J.K., Young, M.R.I. Tumors induce the formation of suppressor endothelial cells in vivo . Cancer Immunol. Immunother., 59:267-277, 2010.
Sharma S, Gillespie MB, Palanisamy V, Gimzewski JK. Quanitative nano-structure and single molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes. Langmuir 2011; 6: 14394-400.
Talwar S, Carroll B, Liu A , Gillespie MB, Palanisamy V. Hypoxia-induced cleavage of
HuR regulates c-Myc expression in head and neck oral squamous cell carcinoma. J Biol
Chem. 2011; 286: 32333-43.
Walker, D.D., Reeves, T.D., de Costa, A.-M. Schuyler, C., Young, M.R.I. Immunological modulation by 1α,25-dihydroxyvitamin D
3
in patients with squamous cell carcinoma of the head and neck. Cytokine, 58:448-454, 2012.
Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. 1 alpha, 25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.
Hum Immunol.
2010; 71: 659-665.
Walsh, J.E., Young, M.R.I. Interrelationship between protein phosphatase-1 and TGFβ in regulating motility and cytoskeletal architecture of endothelial cells. Anticancer Res.,
30:4861-4866, 2010.
Walsh, J.E., Young, M.R.I. TGFβ regulation of focal adhesion proteins and motility of premalignant oral lesions via protein phosphatase-1. Anticancer Res, 31:3159-3164,
2011.
Young, M.R. Endothelial cells in the eyes of an immunologist. Cancer Immunol
Immunother, in press, 2012.
2. Is clinical research in head and neck cancer carried out in the institution(s)?
Yes ____X____ No ________
5

If yes, briefly describe all clinical studies ongoing or completed in the last two years.
Please distinguish protocol from non-protocol studies. Describe the source of funding and list peer-reviewed publications in the past three years.
-- The following table summarizes all ongoing and recently-closed clinical trials:
Study Title Type
CT Perfusion in Head and Neck Cancer
A Randomized, Open Label Controlled Phase II Trial of
Chemotherapy with or without Panitumumab as First Line
Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer
Phase II Study of Single Agent Cetuximab for Treatment of
High Risk Premalignant Upper Aerodigestive Lesions
An International Phase II Randomized, Double-Blinded
Placebo-Controlled Multicenter Study to Assess the
Efficacy of ZD6474 versus Placebo in Subjects with
Unresectable or Metastatic Medullary Thryoid Cancer
An International Randomized, Double-Blinded Phase 3
Efficacy Study of XL184 Versus Placebo in Subjects with
Unresectable or Locally-Advanced Medually Thyroid
Cancer
Immunotherapy to Prevent Oral Premalignant Lesion
Recurrence and Oral Cancer
Targeting mTOR as a Novel Mechanism-Based Therapy for
Head and Neck Cancer
Quality of Life in Head and Neck Cancer Patients and Their
Caregivers
Vitamin D Plus Celecoxib to Stimulate Intratumoral Immune
Reactivity
Observational Study of Swallowing Function After
Treatment of Advanced Laryngeal Cancer
A Phase III Study of Postoperative Radiation Therapy +/-
Cetuximab for Locally-Advanced Resected Head and Neck
Cancer
Institutional
Industry
IIT
Industry
Industry
Industry
Institutional
Institutional
External /Peer-Reviewed
IIT
Cooperative Group
Investigator
Rumboldt
O’Brien
Gillespie
Hornig
Fernandes
Young
Day
Sterba
Young
Gillespie
Sharma
6

A Randomized, Double-Blind, Phase II Trial of Everolimus
Versus Placebo as Adjuvant Therapy in Patients with
Locally-Advanced Squamous Cell Cancer of the Head and
Neck
A Randomized Double-Blind Phase 2 Safety Study of
Cetuximab Using ImClone vs. Boehringer Ingelheim
Manufacturing Processes in Combination with Cisplatin or
Carboplatin and 5-FU in the First Line Treatment of
Patients with Locoregionally Recurrent or Metastatic
Squamous Cell Carcinoma of the Head and Neck
A Phase III Randomized Trial of Concurrent Cisplatin and
Radiotherapy with or without Oncovex in Previously
Untreated Patients with Locally Advanced Squamous Cell
Carcinoma of the Head and Neck
Placenta Growth Factor Inhibition in Head and Neck
Cancer
Intervention to Prevent Delayed Diagnosis in Oral Cancer
(Oral Lesion Interview Study)
Randomized, Double-Blind, Multicenter Phase III Study of
REOLYSIN in Combination with Paclitaxel and Carboplatin versus Chemotherapy Alone in Patients with Metastatic or
Recurrent Squamous Cell Carcinoma of the Head and
Neck
Health Behaviors, Quality of Life and Surgical Outcomes in
Individuals with Head and Neck Cancer
Phase I / II Study of PX-866 and Cetuximab
A Randomized Phase II Study of Adjuvant Concurrent
Radiation and Chemotherapy versus Radiation Alone in
Resected High Risk Malignant Salivary Gland Tumors
Phase III Trial of Radiotherapy plus Cetuximab versus
Chemoradiotherapy in HPV-Associated Oropharynx
Cancer
Racial Disparities in Outcomes of Head and Neck Cancer
Patients
A Phase II, Open-Label, Randomized Study of MEHD-
7945A versus Cetuximab in Patients with Recurrent or
Metastatic Squamous Cell Carcinoma of the Head and
Neck Who Have Progressed During or Following Platinum-
Based Chemotherapy
7
IIT
Industry
Institutional
Industry
Cooperative
Cooperative
Institutional
Industry
Industry
Institutional
ITT
Industry
Shirai
Shirai
Shirai
Sutkowski
Davis
O’Brien
Sterba
Shirai
Hornig
O’Brien
Day
O’Brien

Phase I / II Study of PX-866 and Docetaxel in Patients with
Solid Tumors
The SAIL Study: Survivorship and Inspiration for Life
Industry
External /Peer-Reviewed
Shirai
Sterba
-- Publications on clinical topics related to Head and Neck cancer published by MUSC researchers in the last three years include the following:
Albergotti WG, Nguyen SA, Zenk J, Gillespie MB. Extracapsular dissection for benign parotid tumors: a meta-analysis. Laryngoscope 2012; Epub ahead of print.
Banks CA+, Ayers CM, Hornig JD, Lentsch EJ, Day TA, Nguyen SA, Gillespie MB.
Thyroid disease and compressive symptoms.
Laryngoscope . 2012 Jan;122(1):13-6
Brodsky MB, McFarland DH, Dozier TS, Blair J, Ayers C, Michel Y, Gillespie MB, Day TA,
Martin-Harris B. Respiratory-swallow phase patterns and their relationship to swallowing impairment in patients treated for oropharyngeal cancer. Head Neck 2010; 32: 481-489.
Byrd JK+, Nguyen SA, Ketcham A*, Hornig J, Gillespie MB, Lentsch E. Minimally invasive video-assisted thyroidectomy versus conventional thyroidectomy: a cost-effective analysis. Otolaryngology, Head Neck Surg . 2010 Dec; 143(6):789-94
Byrd JK, Yawn RJ, Wilhoit CST, Sora ND, Meyers L, Fernandes J, Day TA. Well differentiated thyroid carcinoma: Current Treatment. Current Treatment Options in
Oncology ; 1(11), 2012. (Epub ahead of print).
Cannon TY, Strub GM, Yawn RJ, Day TA. Oromandibular Reconstruction. Clinical
Anatomy , 25(1); 2011 Jan; 108-119.
Carroll W, Wilhoit CS, Intaphan J, Nguyen SA, Gillespie MB .
Snoring management with nasal surgery and upper airway radiofrequency ablation. Otolaryngol Head Neck Surg .
2012; 146: 1023-27.
Davis BK: Facial Prosthetics. Current Opinion in Otolaryngology/Head and Neck
Surgery . 18(4):332-40, 2010.
Davis KS, Welsh CT, Hawes RH, Gillespie MB. Pathology quiz case 3: Heterotopic gastric mucosa. Arch Otolaryngol Head Neck Surg . 2011; 137: 831.
Fancy T, Gallagher D, Hornig JD.
Surgical Anatomy of the Thyroid and Parathyroid
Glands. Otolaryngol Clin North Am . 2010 Apr; 43(2):221-7, vii.
Gillespie MB, Ayers CM, Nguyen SA, Abidin MR. Outcomes of hyoid myotomy and suspension using a mandibular screw suspension system. Otolaryngol Head Neck Surg.
2011; 144: 225-229.
Gillespie MB, Intaphan J, Nguyen SA. Endoscopic-assisted management of chronic sialadenitis. Head Neck 2011; 33: 1346-51.
8

Gillespie MB, Koch M, Iro H, Zenk J. Endoscopic-assisted gland-preserving therapy for chronic sialadenitis: a German and U.S. Comparison. Arch Otolaryngol Head Neck Surg.
2011; 137: 903-908.
Gillespie MB, Reddy RP, White DR, et al. A trial of drug-induced sleep endoscopy in the surgical management of sleep-disordered breathing. Laryngoscope 2012; Epub ahead of print.
Gillespie MB, Stachiw ND+, Way J*, Lentsch EJ, Richardson MS, Nguyen SA, Day TA,
Hornig JD. Neural outcomes after plasma knife dissection: A pathologic study and clinical correlation. Head Neck . 2010 Oct; 32(10):1321-7.
Gillespie MB, Wylie P, Lee-Chiong T, Rapoport DM. Effect of palatal implants on CPAP pressure and compliance. Otolaryngol Head Neck Surg.
2011; 144: 230-236.
Harvey RJ, Pitzer G, Nissman DB, Buchmann L, Rumboldt Z, Day T., Schlosser RJ.
PET/CT in the assessment of previously treated skull base malignancies. Head Neck .
2010 Jan: 32(1)76-84.
Kearney PL, Watkins JM, Shirai K, Wahlquist AE, Fortney JA, Garrett-Meyer E, Gillespie
MB, Sharma AK. Salvage resection for isolated local and/or regional failure of head and neck cancer following definitive concurrent chemoradiotherapy: case series and review of the literature. McGill J Med.
2011; 13(2): 29.
Muzaffar W, Reddy R, Gillespie MB, Nguyen S, Lentsch E, Hornig JD. A Prospective,
Double-Blinded, Controlled Trial Evaluating Wound Drainage and Post-Operative
Complications with EVICEL Fibrin Sealant Use in Thyroidectomy. Submitted for publicationLaryngoscope , April 2012.
Muzaffar W, Nguyen S, Terrell Z, Hornig JD. Should Obesity be a Contraindication to
Minimally Invasive Video-Assisted Thyroidectomy? Submitted for publication-
Laryngoscope , April, 2012.
Ngyuen S, Walker D, Gillespie MB, Gutkind JS, Day TA. MTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. Current Treatment options in
Oncology . Springer 2011.
Onicescu G, Hill EG, Lawson AB, Korte JE, Gillespie MB. Joint disease mapping of cervical and male oropharyngeal cancer incidence in blacks and whites in South
Carolina. Spatial Spatio-tempero Epidemio.
2010; 1: 133-141.
Oyer SL, Patel KG. Endoscopic brow approach for excision of traumatic frontal osteoma.
International Journal of Pediatric Otorhinolaryngology . 76(8). 1211-1213, Aug 2012.
PMID 22564246
Reddy R, White DR, Nguyen SA, Gillespie MB. Obstructive parotitis secondary to an acute masseteric bend. ORL J Otorhinolaryngol Relat Spec. 2011; 74: 12-15.
Reed SG, Cartmell KB, Duffy NG, Wahlquist AE, Sinha D, Hollinger A, Bode A, Alberg
AJ, Day TA. Oral cancer Preventive Practices of South Carolina Dentists and
Physicians. J Cancer Educ 2010 Jan 16. [(Epub ahead of print)].
Reeves TD, Hill EG, Armeson KE. Gillespie MB. Cetuximab therapy for squamous cell carcinoma of the head and neck: a systematic review of the data. Otolaryngol Head Neck
Surg.
2011; 144: 676-684.
9

Saddoughi SA, Garrett-Mayer E, Chaudhary U , O’Brien PE, Afrin LB, Day TA, Gillespie
MB, et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Can Res.
2011; Jul 26: Epub ahead of print.
Scmedes G , Banks C, Malin B, Skoner J. “Massive flap donor sites and the role of negative pressure therapy.” Otolaryngol HNS (in press).
Watkins JM, Zauls AJ, Wahlquist AH, Shirai K, Garrett-Mayer E., Gillespie MB, Day TA,
Sharma AK. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope . 2010 Feb; 120(2)236-42.
Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE,
Newman JG, Carroll WR, Gillespie MB, et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck 2011; 33: 1666-
74.
Woodworth BA, Chandra RA, Hoy MJ, Lee FS, Schlosser RJ, Gillespie MB.
Randomized-controlled trial of hyaluronic acid/carboxymethylcellulose dressing after endoscopic sinus surgery. ORL 2010; 72: 101-105.
Zeidan YH, Zauls AJ, Bilic M, Lentsch EJ, and Sharma AK. Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report. J Med Case Reports 2010, May 22; 4:147.
Zenk J, Koch M, Klintworth N, Konig B, Konz K, Gillespie MB, Iro H. Sialendoscopy in the diagnosis and treatment of sialolithiasis. A study in more than 1000 patients.
Otolaryngol Head Neck Surg . 2012; Epub ahead of print.
3. Are there laboratory research facilities available to head and neck fellows?
Yes ___X____
If yes, please describe.
No ________
There are multiple laboratory research facilities available to the Fellows. Laboratories headed by the following faculty members welcome the Fellows to participate in basic science or translational research:

Andrew Jakymiw PhD ( NIH/NIDCR )

Keith L. Kirkwood DDS, Phd – ( NIH/NIDCR/NCRR )

Bonnie Martin-Harris , PhD, CCC-SLP, BRS-S, ASHA Fellow – ( NIDCD )

Besrim Ogretmen, PhD – (NIH)

Viswanathan Palanisamy PhD – (NCRR/NIDCR)

Sue G. Reed DDS, PhD – (NIH/NIDCR)

Steven A. Rosenzweig, PhD – (NIH/NCI/NCRR/DOD)

M. Rita I Young, PhD – (NIH/NIDCR/NCI)
10

4. Describe the fellow’s research program. Please note the following:
It is expected that all fellows will be involved in clinical research projects and participate in the presentation/publication of results. It is recommended that fellows in 24 month programs should have dedicated (protected or block) time available for laboratory research.
--The involvement of the Head & Neck Fellow in research efforts associated with the
MUSC Head & Neck Tumor Program is multifaceted. Head & Neck Fellows participate in all on-going clinical trials and attend all Clinical Trial meetings. Each Fellow is required to develop and complete a minimum of one clinical research project per year with publication of results and presentation at a national meeting. Fellows are also expected to participate in a translational research project. Additionally, they are expected to produce at least one clinical review paper, book chapter or other non-peer reviewed publication.
1.
D. FELLOWSHIP EDUCATION INFORMATION
List all teaching sessions in which the fellows participate regularly.
Type of Conference Frequency
Multidisciplinary Tumor Board Weekly
Role of Fellow
Departmental Grand Rounds Weekly
Morbidity & Mortality Meetings Monthly
Resident Lecture Series Weekly
Head & Neck In-patient Rounds Daily
H & N Clinical Trials Meeting Monthly
Present cases / didactics
Present / discuss
Present / discuss
Present / attend
Supervise / attend
Discuss / attend
2.
H & N Translational Sciences Monthly Attend / participate
Describe the teaching responsibilities of the fellow.
-- The Head & Neck Fellow will have responsibility for teaching at multiple levels. The
Fellow will supervise daily rounds with the house-staff, mid-level practitioners and medical students. The Fellow will provide oversight and assistance on a daily basis in the provision of in-patient and out-patient care. Teaching of residents will also be performed in the operating room, and the Fellow plays a role similar to full faculty in this regard. Direct teaching of medical and dental students will be performed on a daily basis in the context of the operating room, hospital-based and outpatient clinical activities.
Fellows will also present formal didactic lectures to residents and medical students at least twice per year.
3. What is the number of head and neck cancer patients evaluated by Phase III program for last academic year?
11

4.
TOTAL NUMBER EVALUATED:
Previously untreated patients:
Previously treated patients:
Consult only:
____755 (new pts.)___
____232____________
____523____________
____10_____________
Number of patients treated surgically: ____612____________
Number of patients treated non-surgically (XRT/Chemo): ___________________
Head and neck patients evaluated by Speech Pathology: ____267____________
Head and neck patients treated by Maxillofacial
Prosthetic Department: ____ 337___________
Number of new patients for whom the fellow will have primary responsibility/yearly: _____90____________
Total number of patients fellows will operate upon yearly either as primary surgeon or first assistant to a resident: _____280___________
6.
5.
Number of outpatient visits fellow will observe yearly _____250___________
Will the fellow be assigned blocks of time in other departments?
Yes ____X____ No _________
If yes, please describe briefly.
-- The Head & Neck Fellows are required to spend time in other departments providing care to Head and Neck cancer patients or providing ancillary clinical services. During the course of a one year training program, Fellows are required to spend at least ½ day working with the following services in either the operating room or other clinical setting: Neurosurgery, Radiation Oncology, Medical
Oncology, Speech Pathology, Maxillofacial Prosthodontics, Oral Pathology,
Surgical Pathology, Neuroradiology, Oral Surgery, Dermatologic MOHS surgery and the Tumor Procurement Center.
Indicate the number of oncologic cases performed in the previous 12 months by head and neck surgical teaching faculty, which would have been available to the fellow last year. Record according to category.
Salivary gland surgery: ________343________
Nose and paranasal sinus and skull base surgery:
Lip surgery:
Oral cavity surgery:
________363________
________33_________
________495________
12

Neck surgery:
Tracheal surgery:
Larynx and pharynx surgery:
Thyroid and parathyroid surgery:
Ear and temporal bone surgery:
Regional/myocutaneous flaps:
_______751_________
_______331_________
_______395_________
_______52__________
_______121_________
_______148_________
AM
PM
1.
7. Indicate total number of chief residents on the head and neck service at any one time with head and neck fellow: _______1___________
Please explain:
-- Typically, staffing of the in-patient service involves three residents: a chief resident, a junior resident and an intern. The Head & Neck Fellow has responsibility for overseeing the housestaff team, including supervision of daily morning rounds and consultation on all major care decisions regarding Head & Neck in-patients. Fellows function as junior faculty serving a supervisory role in terms of daily care of in-patients and functioning as liaisons between housestaff and senior faculty members. In the operating room, Fellows will frequently work with chief residents on major cases and supervise junior faculty on other cases.
E. Fellowship Service Information
Give a narrative summary of clinical responsibilities during fellowship:
Underline a. Please use a block diagram to demonstrate how a fellow will spend an average week on head and neck surgical oncology. b. Please use a block diagram to show how a fellow will spend each year of fellowship.
These block diagrams should be attached to the application and clearly labeled.
Monday
- H&N Clinic or OR
-Tumor Board
Tuesday
- Endocrine
Surgery Clinic or OR
-OR
Wednesday
- H&N Clinic or
OR
- H&N Clinic or OR
- H&N Clinic or
OR
Thursday
- H&N Fellow
Clinic or OR
Friday
- H&N Fellow
Clinic
- OR or
Research
13

3.
4.
2. How will the fellow interact with the current surgical residency programs and other fellowship programs in terms of head and neck surgery?
-- All major head and neck procedures are typically done within the department, and virtually all of these cases are available to the Fellow as accords with other clinical responsibilities. For cases in which the patient’s disease requires treatment by other surgical services, the Fellow may work collaboratively with residents and Fellows from other disciplines. Most commonly, such collaborations occur between the Head & Neck fellows and faculty or trainees from Neurosugery, Thoracic Surgery, Dermatologic Surgery and Oral-
Maxillofacial Surgery.
What academic title will the fellow carry?
Clinical Instructor
Outline the fellow’s outpatient or clinical responsibilities?
-- The Fellow has three different spheres of clinical responsibility. The Fellow is responsible for overseeing the housestaff in the caring for all Head & Neck surgery in-patients. In this capacity, the Fellow rounds each morning on all Head and Neck patients with the housestaff team as supervisors. Key management decision are made in consultation with senior faculty. In terms of new patient evaluation and outpatient manage ment, there is a ½ day per week Head & Neck clinic staffed by the Fellows. Fellows evaluate new patients each week and have primary management responsibility for all patients seen in their clinic. All patients seen in the Fellows’ clinic with new diagnoses of cancer are reviewed at our weekly Head and Neck Multidisciplinary Tumor Board meeting. All patients evaluated in the Fellows’ clinic who require surgical intervention are operated upon by the Fellows with the supervision or assistance of senior faculty as appropriate. In this manner, Fellows have the opportunity to function largely independently as junior faculty.
5. Please attach the surgical experience reports for all of the resident physicians in this program completing their training during the past academic year.
14

15

16

1.
F. Fellowship Personnel Information
List head and neck surgeons and academic rank who will regularly work in the operating room with the fellow.
17

NAME:
Terry A. Day
Joel Cook
Marion B. Gillespie
Joshua D. Hornig
Eric J. Lentsch
Barry T. Malin
Ted Meyer
Zoran Rumboldt
Roy Sessions
Alex Vandergrift
J. David Osguthorpe
Krishna G. Patel
Judith M. Skoner
RANK:
Professor
Associate Professor
Professor
Associate Professor
Assistant Professor
Assistant Professor
Assistant Professor
Professor
Assistant Professor
Professor
Professor
Assistant Professor
Assistant Professor
2. List names and titles of all professional staff who will regularly participate in education of the fellow.
NAME: RANK:
Terry A. Day Professor
Joel Cook
Betsy K. Davis
Joytika Fernandes
Marion B. Gillespie
Joshua D. Hornig
Eric J. Lentsch
Barry T. Malin
Ted Meyer
J. David Osguthorpe
Krishna G. Patel
Associate Professor
Associate Professor
Associate Professor
Professor
Associate Professor
Assistant Professor
Assistant Professor
Assistant Professor
Professor
Assistant Professor
18

Roy Sessions
Anand Sharma
Keisuke Shirai
Professor
Professor
Assistant Professor
3.
Judith M. Skoner
Alex Vandergrift
Assistant Professor
Assistant Professor
Please provide curricula vitae and bibliographies of program director, assistant program director, and other individuals who are important to the program. Include complete CV of
Program directors. All other CV’s may be limited to two (2) pages.
Curriculum Vitae Attachments:
Julie A. Blair, M.A., CCC-SLP – Speech – Language Pathologist
Britni Carnes, M.S., CCC-SLP – Speech - Language Pathologist
Mary Beth Chalk MSN, RN, APRN-BC – Head & Neck Surgical Oncology Nurse Practitioner
Betsy K. Davis, DMD, MS – Associate Professor, Department of Otolaryngology, Director of
Maxillofacial Prosthodontics
Terry A. Day MD – Professor & Vice-Chairman, Department of Otolaryngology, Director of Head and Neck Surgery
Joytika Fernandes MD -- Associate Professor, Division of Endocrinology
Department of Medicine
Elizabeth Garrett-Mayer PhD – Professor, Department of Biostatistics and Epidemiology
M. Boyd Gillespie MD, MsC – Professor, Department of Otolaryngology
Jennifer L. Harper MD – Associate Professor, Department of Radiation Oncology
Joshua D. Hornig MD – Associate Professor, Department of Otolaryngology
Andrew Jakymiw PhD – Assistant Professor, Department of Craniofacial Biology
Keith L. Kirkwood DDS, Phd – Professor & Chair, Department of Craniofacial Biology
Eric J. Lentsch, MD – Assistant Professor, Department of Otolaryngology
Barry T. Malin, MD, MPP – Assistant Professor, Department of Otolaryngology
Bonnie Martin-Harris , PhD, CCC-SLP, BRS-S, ASHA Fellow – Professor of Otolaryngology
Brad W. Neville, DDS – Assistant Professor, Department of Oral Pathology
19

Shaun A. Nguyen MD, MA, CPI – Associate Professor, Director of Clinical Research,
Department of Otolaryngology
Paul E. O’Brien MD – Division of Hematology / Oncology, Department of Medicine
Besrim Ogretmen PhD – Professor, Department of Biochemistry and Molecular Biology
Jennifer R. Page RN, MSN, NP-C – Head & Neck Surgical Oncology Nurse Practitioner
Viswanathan Palanisamy PhD – Assistant Professor, Department of Craniofacial Biology
Krishna G. Patel MD, PhD -- Assistant Professor of Otolaryngology, Director of Facial Plastic and Reconstructive Surgery
Sue G. Reed DDS, PhD – Associate Professor, Department of Pediatrics
Mary Richardson DDS, MD – Professor, Department of Pathology and Laboratory Medicine,
Director of Surgical Pathology Services
Steven A. Rosenzweig, PhD – Professor, Department of Cell and Molecular Pharmacology and
Experimental Therapeutics
Zoran Rumboldt MD, MS – Professor of Radiology, Division Chief - Neuroradiology
Rodney J. Schlosser MD – Professor, Department of Otolaryngology, Director of Rhinology and
Sinus Surgery
Anand Sharma MBBS – Professor, Department of Radiation Oncology
Roy Sessions MD – Professor, Department of Otolaryngology
Keisuke Shirai MD, MSCR – Assistant Professor, Division of Hematology and Oncology,
Department of Medicine
Judith M. Skoner MD – Assistant Professor, Department of Otolaryngology
Maria Spampinato MD – Associate Professor, Department of Radiology
Katherine R. Sterba, MPH, PhD – Assistant Professor, Department of Medicine, Department of
Biostatistics and Epidemiology
M. Rita I Young, PhD – Professor, Department of Otolaryngology
20